AR-42, also known as (S)-HDAC-42, is a phenylbutyrate-based histone deacetylase (HDAC) inhibitor. HDACs are enzymes that determine acetylation status of histones, thereby affecting chromatin structure and regulating the expression and activity of numerous proteins involved in both cancer initiation and cancer progression. AR-42 possesses antitumor activity at multiple cellular levels. It is currently in Phase I/Ib trials for hematological malignancies and solid tumors.

Clodazon (AW 142446) is an antidepressant drug investigated in Germany in the 1960s. In animal models, clodazon inhibits the catalepsy induced by tetrabenazine and it potentiates the effect of catecholamines, both effects being of the order experienced with imipramine. In clinical trials, about 2/3 of the patients showed a positive antidepressive effect with few side effects.

Iodoantipyrine I-131 is a radiopharmaceutical nonsteroid anti-inflammatory compound evaluated for coronary blood flow measure and as a total body water marker. In vivo results suggested that soon after injection of 4-I131 AP (Iodoantipyrine I-131) in rats , significant and increasing quantities of the I131 tracer were detached from the antipyrine molecule in a form which is more diffusible than 4-I131 AP. Evidence for a similar phenomenon was seen in other species. There were qualitative differences in the behavior of antipyrine and 4-I131 AP when injected in animals, and these may invalidate the use of 4-I131 AP as a substitute for antipyrine in studies of body composition.

Ripazepam (CI 683 or pyrazapon) is a pyrazolodiazepine that has anxiolytic effects. It is related to certain benzodiazepines such as zolazepam. In animal studies, it showed anxiolytic effects without sedative or depressant effects. In rats, it did not elicit a tumorigenic potential. Although ripazepam was found significantly superior to placebo and was well tolerated in neurotic patients, it has never been marketed for clinical use.

Metalol is an antagonist at beta-adrenergic receptors.

Disofenin is an iminodiacetic acid derivative with no known pharmacologic actions at the doses recommended. Technetium Tc 99m disofenin injection is a radiopharmaceutical. Technetium Tc99m disofenin is indicated as a hepatobiliary imaging agent. Technetium Tc99m disofenin is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain, fever, jaundice, right upper quadrant tenderness and mass or rebound tenderness, but not limited to these signs and symptoms. Itching at the site of injection progressing to erythema multiforme has been reported following single administration. Also, rare cases of chills and nausea have been reported.

Thyromedan is a thyroalkanoic acid derivative with hypocholesterolemic activity. In clinical trials, Thyromedan in daily doses of 8 to 32 mg caused a decrease in serum cholesterol levels. The serum total triglycerides and the α- and β-lipoprotein partition of cholesterol and triglycerides were unaffected.

Modecainide is a benzanilide derivative patented by American pharmaceutical company Bristol-Myers Co. as type Ic antiarrhythmic agent. Modecainide is a major metabolite of Encainide, a class Ic antiarrhythmic, with comparable antiarrhythmic activity. Modecainide is never marketed because of its frequent proarrhythmic side effects.

Seperidol (also known as clofluperol or R9298), a butyrophenone derivative that was developed as an antipsychotic agent. This compound was studied as a long-acting neuroleptic. However, information about the current use of seperidol is not available.

Mesuprine is a β-adrenergic-receptor mimetic agent. It is a smooth muscle relaxant that prevents uterine contractility and premature labor.